ORCHIDPHAR

Orchid Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2016.

Orchid Pharma Limited has informed the Exchange regarding Statement on Impact of Audit Qualifications - for the eighteen months period ended March 31, 2015.

Orchid Pharma Limited has submitted to the Exchange the details of voting results of the Annual General Meeting of the Company held on the September 28, 2016 along with Report of Scrutinizer.

Orchid Pharma Limited has submitted to the Exchange a copy of Proceedings of the Annual General Meeting of the Company held on September 28, 2016 along with Chairman's Speech.

Orchid Pharma Limited has informed the Exchange regarding disclosure under Regulation 30(5) of SEBI (LODR) Regulations, 2015.

Orchid Pharma Limited has informed the Exchange that ORCHID has received a Notice under Section 13(4)(a) of the SARFAESI ACT, 2002 from SICOM Limited, for the property situated at "Orchid Towers", 313, Valluvarkottam High Road, Nungambakkam, Chennai- 600 034. Based on the said Notice, SICOM Limited has taken symbolic possession on September 09, 2016. However, the Company is in an advanced stage of discussions to raise resources, so that the loan availed from SICOM can be settled expeditiously.

Orchid Pharma Limited has submitted to the Exchange a copy of the notice published in the newspaper regarding the Annual General Meeting, evoting and bookclosure.

Orchid Pharma Limited has informed the Exchange that the Register of Members and Share Transfer Books of the Company shall remain closed from September 19, 2016 to September 28, 2016 (both days inclusive) for the purpose of Annual General Meeting of the Company has been proposed to be held on September 28, 2016.

Orchid Pharma Limited has informed the Exchange regarding Press Release dated August 13, 2016 title "Orchid Pharma registers turnover of Rs. 190.9 crore in Q1 FY17, EBITDA of Rs. 22.3 crore."

Orchid Pharma Limited has submitted to the Exchange the standalone financial results along with the Limited Review Report for the period ended June 30, 2016.

Orchid Pharma Limited has informed the Exchange regarding the Statement on Impact of Audit Qualification for the financial year ended March 31, 2016.

Orchid Pharma Limited has informed the Exchange that the Company have received a letter dated May 31, 2016 from Shri S Krishnan, non-executive & non-independent Director wherein he has resigned from the Board and Committee of Board of the Company with effect from May 31, 2016 and the Board has accepted his resignation.

Orchid Pharma Limited has informed the Exchange regarding a press release dated May 27, 2016 titled "Orchid Pharma registers turnover of Rs 879 crore in FY 16".

Orchid Pharma Limited has submitted to the Exchange the standalone & consolidated financial results along with the Auditors Report for the period ended March 31, 2016.

Orchid Pharma Limited has informed the Exchange that the SEBI (Prohibition of Insider Trading) Regulations, the trading window for dealing in the securities of the Company shall remain closed for all the insiders from May 18, 2016 to May 30, 2016 (both days inclusive).

K Raghavendra Rao, Rajagopal K, Bhuvana Mani & Kota Swarnalatha has submitted to the Exchange vide letter dated April 08, 2016 a copy of disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Orchid Pharma Limited has informed the Exchange that the Company received the Establishment inspection report (EIR) from USFDA based on the successful inspection closure for the API manufacturing facility located at Alathur, Kancheepuram District, India. The facility was inspected by USFDA in the month of August 2015.

Orchid Pharma Limited has informed the Exchange regarding a press release dated March 17, 2016 titled "Orchid receives final USFDA nod for Rasagiline generic formulation".

Orchid Pharma Limited has informed the Exchange regarding a press release dated February 10, 2016 titled "Orchid Pharma registers turnover of Rs 204 crore in Q3 FY16, EBITDA of Rs 39 Crore".

Orchid Pharma Limited has submitted to the Exchange the standalone financial results along with the Limited Review Report for the period ended December 31, 2015.

Orchid Pharma Limited has informed the Exchange that Industrial Development Bank of India has withdrawn the nomination of Shri Nagaraj Garla and instead appointed Shri Rabinarayan Panda, Chief General Manager, IDBI Bank Ltd, Chennai as its nominee. He was appointed as a Nominee Director of the Company at the Board meeting held on December 30, 2015.

Orchid Pharma Limited has informed the Exchange that the Company is pleased to announce that orchid received the Establishment Inspection Report (EIR) from USFDA based on the successful inspection closure for the formulation manufacturing facility located at Irungattukottai, Sriperumbudur, Kancheepuram District, India.The Facility was inspected by USFDA in the month of May 2015.

Orchid Pharma Limited has informed the Exchange that Orchid Europe Limited, UK a wholly-owned subsidiary of Orchid Pharma Limited, India has entered into a long term financial arrangement to avail up to US$ 800 million {US Dollar Eight Hundred Million) as loan with Line Trust International, Guernsey, UK. This funding will help the company explore new growth opportunities while enabling the current business achieve incremental value.

Members of the Exchange are hereby informed that the name of the Company Orchid Chemicals & Pharmaceuticals Limited shall be changed to Orchid Pharma Limited and the trading symbol of the Company shall be changed from ORCHIDCHEM to ORCHIDPHAR w.e.f. December 21, 2015.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange that production operations of the Company's Bulk Drugs Plant located at Alathur, Tamil Nadu have been disrupted from December 02, 2015, due to flooding at the factory premises caused by heavy rains in Chennai.The Company have now recommenced the operations in a phased manner. However, the Sterile Manufacturing Section would need to be verified for Sterility and this would take a few more days for becoming fully operational.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange titled "Orchid Pharma registers turnover of Rs 211 crore in Q2 FY16, EBITDA of Rs 43 crore."

Orchid Chemicals & Pharmaceuticals Limited has submitted to the exchange the standalone financial results along with the Limited Review Report for the period ended 30-Sep-2015.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange that the members of the Company at the Annual General Meeting held on September 15, 2015 have approved to change the name of the Company to "Orchid Pharma Limited" and the special resolution was passed with requisite majority. Based on this, the Company had made an application to Registrar of Companies, Tamilnadu, for change of name and the Registrar of Companies have approved the change in the name of the Company to "Orchid Pharma Limited."

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange that the Allotment Committee of the Board of Directors at their meeting held on October 09, 2015 has allotted 3,702,450 equity shares of Rs.10/ each at a price of Rs.49.79/- (Including a premium of Rs. 39.79/- per share) as the second and final tranche to the Promoter group Company M/s Orchid Healthcare Private Limited on Preferential Basis as per the Corporate Debt Restructuring (CDR) Scheme approved by the CDR Empowered Group in terms of CDR Scheme.

News about Orchid Chemicals & Pharmaceuticals Limited.The media had reports that "Orchid Pharmaceuticals in talks with banks to rejig debt".The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company.Orchid Chemicals & Pharmaceuticals Limited has vide its letter inter-alia stated, "The company is currently in talks with banks to explore the possibility of converting its rupee debt into dollar denominated debt. This plan is to try and reduce the

The Exchange has sought clarification from Orchid Chemicals & Pharmaceuticals Ltd., with respect to recent news item captioned "Orchid Pharmaceuticals in talks with banks to rejig debt". In this regard, the Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such negotiations were taking place and b) Whether you/company are aware of any information that has not been announced to the Exchanges which could explain the aforesaid movement in the trading. The response from the company is awaited.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated August 13, 2015 titled "Orchid Pharma registers turnover of Rs. 256 crore in Q1 FY16, EBITDA of Rs. 59 crore".

Orchid Chemicals & Pharmaceuticals Limited has submitted to the exchange the standalone financial results along with the Limited Review Report for the period ended 30-Jun-2015.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange that the Board has approved the Code of practices and procedures for fair disclosure of unpublished price sensitive information (UPSI).

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange that Orchid has received approval from the US FDA for the Abbreviated New Drug Application (ANDA) for Gemifloxacin Mesylate Tablets (320mg) with 180 days of generic drug exclusivity.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange that the Company has received approval from the USFDA for the Abbreviated New Drug Application (ANDA) for Rivastigmine Capsules in 1.5mg, 3mg,4.5mg,6mg and Felodipine extended-release tablets in 205mg, 5mg,10mg.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange that Shri Sundaram Yuvraj has vacated his office pursuant to Section 167(b) of the Companies Act 2013 from the Board of Orchid and Shri R Kannan has been inducted into the Board of the Company as a Non-Executive, Independent director with effect from May 28, 2015.

Orchid Chemicals & Pharmaceuticals Limited has submitted to the exchange the standalone & consolidated financial results for the period ended 31-Mar-2015.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 28, 2015 titled "Orchid Pharma registers turnover of Rs. 1753 crore in FY15".

Rajagopal K has submitted to the Exchange vide letter dated April 10, 2015 a copy of disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Kota Swarnalatha has submitted to the Exchange vide letter dated April 13, 2015 a copy of disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

K Raghavendra Rao has submitted to the Exchange vide letter dated April 10, 2015 a copy of disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Bhuvana Mani has submitted to the Exchange vide letter dated April 10, 2015 a copy of disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange that the Board of Directors, at a meeting held March 30, 2015, has considered and appointed Smt. Soundara Kumar as a Nominee Directors of OCPL.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange regarding extension of holding Annual General Meeting for the year 2013 - 2015 by 3 months.

SBICAP Trustee Company Ltd has submitted to the Exchange vide its letter dated February 24, 2015 a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Orchid Chemicals & Pharmaceuticals Limited has submitted to the exchange the standalone financial results along with the Limited Review Report for the period ended 31-Dec-2014.

Orchid Health Care Private Limited has submitted to the Exchange vide letter dated December 24, 2014 a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Orchid Healthe care Private Ltd has submitted to the Exchange vide letter dated December 24, 2014 a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Orchid Healthcare Private Ltd has submitted to the Exchange vide letter dated December 24, 2014 a Copy of Disclosure under Regulation 10(6) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.